



2024 WDC Summit

The next 10 years:
From new therapies to brain health

26 March 2024

The decade ahead will be one of significant change in the dementia field. In some countries there are already approved disease modifying treatments, and more treatments for more targets, at different stages of disease and using different mechanisms are on the horizon. The development of new biomarkers marks a significant point of departure. Blood biomarkers will be increasingly used in specialist centres, firstly, and then more routinely in clinical practice. To benefit from treatments patients will need to be diagnosed much earlier in the disease trajectory than is the norm today. The pace of change depends on what both science and health systems can deliver. But, as with other disease areas, cardiovascular and cancer being examples, effectively managing the impact disease has on a population involves effective treatment (therapeutics and timely diagnosis), prevention and care and support.

Programme


09:00 – 09:20 **Welcome**



Lenny Shallcross
Executive Director, WDC



Philip Scheltens
Chair, WDC
Partner, EQT Life Sciences



Joanne Pike
Vice Chair, WDC
President & CEO,
Alzheimer's Association

Event Sponsors



Partner Organisations




09:20 – 10:20 Therapeutics and diagnostics: 10 years of transformation?

This session will address what patients can realistically expect from diagnosis and treatment over the next decade. Panellists will discuss the barriers to developing new treatments and diagnostics and how to integrate them into routine clinical practice.



Chair: Philip Scheltens, *Chair, WDC*
Partner, EQT Life Sciences

Speakers



Art Toga
Provost Professor of Ophthalmology, Neurology, Psychiatry and the Behavioral Sciences, University of Southern California



Prof John O'Brien
Professor of Psychiatry Cambridge, UK



Fiona Ducotterd
CSO, ARUK UCL Drug Discovery Institute




Niranjn Bose
Managing Director, Gates Ventures

10:20 – 11:00 Break (coffee and refreshments served)

11:00 – 12:00 Post-diagnostic experience: 10 years of steady progress?

This session will consider whether over the next 10 years whether affordable and high-quality care, in community and residential settings can be delivered on scale, without significant innovation in technology and service delivery. As health systems introduce treatments, will innovation in care inevitably be squeezed?




Chair: Joanne Pike, *Vice Chair, WDC*
President & CEO, Alzheimer's Association


Speakers




Louise Robinson
Professor of Primary Care and Ageing, Newcastle University



Laurence Geller
Chairman, Loveday Care



Ishtar Govia
Expert Advisor & Independent Researcher Founder & CEO, Amagi Health Ltd




Chris Lynch
Deputy CEO, Alzheimer's Disease International

12:00 – 13:20 Lunch break (food provided)




Philip Scheltens, *Chair, WDC*
Partner, EQT Life Sciences



Conny Helder
The Netherlands Health Minister


Population behaviour: the barrier to timely diagnosis?

This session will focus on attitudes towards dementia diagnosis and what prompts patients to present to clinicians. Will treatments be the biggest driver of attitudinal changes over the next decade or can public policy effectively change individual behaviour?



Chair: Joanne Pike, *Vice Chair, WDC*
President & CEO, Alzheimer's Association


Speakers



Jean Georges
Executive Director,
Alzheimer Europe



Brian Lawlor
Deputy Director,
Global Brain Health Institute




Katrin Seeher
Technical Officer,
World Health Organisation



Kate Lee
Chief Executive,
Alzheimer's Society UK

Case finding or population detection: how should health systems diagnose in the future?

This session will focus on the diagnostic pathway over the next decade and how health systems will reach patients. Panellists will explore how health systems can effectively shift to diagnosing people earlier in the disease trajectory and when health systems should begin to do so.




Chair: Philip Scheltens, *Chair, WDC*
Partner, EQT Life Sciences

Speakers



Chris Fox
Professor of Clinical Psychiatry,
University of Exeter



Howard Fillit
Founder and Chief Scientist,
ADDF



Siddharthan Chandran
Director,
Dementia Research Institute



Hilary Evans
Chief Executive,
Alzheimer's Research UK

Can we stop treatments increasing inequity?

Treatments risk exacerbating existing inequity in dementia between countries and within countries. Are there practical ways of preventing that or is it, in the short term, inevitable?




Chair: Joanne Pike, *Vice Chair, WDC*
President & CEO, Alzheimer's Association

Speakers



Ryoji Noritake
Director,
Health and Global Policy Institute



Survana Alladi
Neurologist,
NIMHANS



George Vradenburg
Chairman,
Davos Alzheimer's Collaborative
and UsAgainstAlzheimer's

Clinical meaningfulness: do we know what we are aiming for?

Treatments and diagnostics come with significant costs for health systems. Providing good care for someone over the dementia journey is significantly underfunded. How does clinical meaningfulness get measures to understand the benefit of new treatments?



Chair: Philip Scheltens, *Chair, WDC*
Partner, EQT Life Sciences

Speakers



David Llewellyn
Professor of Clinical
Epidemiology and Digital Health,
University of Exeter



Argonde Van Harten
University of Amsterdam



Johannes Streffer,
Senior Vice President,
Lundbeck

15:45 – 16:30 **Maintaining brain health: 10 years of incremental progress?**

This session will address whether there is a case for delivering on scale programmes focused on brain health and prevention, whether from the public policy perspective there is sufficient evidence on the benefit of interventions aimed at individuals, and whether there is evidence broader behavioural change campaigns would have impact.



Chair: Joanne Pike, *Vice Chair, WDC*
President & CEO, Alzheimer's Association

Speakers



Sarah Lock
Senior Vice President for
Policy & Brain Health,
AARP



Melissa Chan
University of Luxembourg
Senior Atlantic Fellow,
Global Brain Health Institute



Franca Gatto
Director,
Division of Aging, Seniors & Dementia,
Government of Canada


16:30 – 17:15 **What can the unexpected deliver: disruption in the decade ahead?**

This session will address how public policy can stimulate innovation and disruption across care, research and prevention.




Chair: Philip Scheltens, *Chair, WDC*
Partner, EQT Life Sciences

Speakers



June Raine
CEO,
Medicines and Health Care products
Regulatory Agency (MHRA)



Joanne Pike
Vice Chair, WDC
CEO & President,
Alzheimer's Association



Siddharthan Chandran
Director,
Dementia Research Institute

17:15 **Closing drinks reception**

Speakers

Suvarna Alladi is Professor of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, India. Dr Alladi was a Commonwealth research fellow in cognitive and behavioural neurology at Cambridge UK. She established one of the first memory clinics in India that provides multi-disciplinary care to more than 3000 patients with dementia. Her areas of interest are cross-cultural cognitive assessment, Frontotemporal dementia, atypical Alzheimer's disease and vascular cognitive impairment. Dr Alladi's group coordinated a multicentric study that adapted cognitive tests for different Indian languages and for illiterates. Her work also focuses on investigating the influence of life-course experiences that include bilingualism, education and social engagement on cognitive resilience. In the background of a rapidly rising burden of dementia, creating awareness and organising community support for dementia became a focus of the Alzheimer's disease NGO she co-founded. Dr Alladi has also made an effort to represent priorities of less-developed societies in international platforms and meetings. She is World Dementia Council Member, Chair of World Federation of Neurology, Special interest group on Aphasia & Cognitive disorders.

Niranjan Bose is the Managing Director for Health & Life Sciences at Gates Ventures, LLC, where he also serves as a Health & Life Sciences Advisor to Mr. Bill Gates. Gates Ventures' programmatic investments in the Alzheimer's field include the AD Diagnostics Accelerator, Dementia Discovery Fund (DDF), EQT Dementia Fund, AD Data Initiative and the European Platform for Neurodegenerative Diseases (EPND). Prior to joining Gates Ventures in 2014, he was the Chief of Staff to the President of the Global Health Program at the Bill & Melinda Gates Foundation.

Melissa Chan works with tri-sector partners (business, government and nonprofit) in health and social care to spearhead service design, knowledge translation, and go-to-market projects. She is currently at the University of Luxembourg leading the co-development of a brain health workplace programme with companies. Melissa has a keen interest in brain health ageing dementia and carer support – particularly in the intersection of research and translation into practice and in bringing evidence-based interventions to diverse populations. She has led multiple initiatives related to care and support delivery for dementia including CARA by Dementia Singapore a national platform to facilitate the safe return of people living with dementia. Melissa is the Founder of Project We Forgot a platform for carers that provides support resources across the dementia care journey. She was previously with ECON Healthcare Group and Homage an on-demand technology care solution where she worked with corporations government agencies healthcare institutions and social service organisations in Singapore and Malaysia. She is a Senior Atlantic Fellow with the Global Brain Health Institute (GBHI) Trinity College Dublin and previously President of the World Young Leaders in Dementia (WYLD) Network driving dementia innovation across disciplines and borders.

Siddharthan Chandran is Director of the UK Dementia Research Institute, and an expert in neurodegenerative diseases. He trained in neurology at Queen Square, UCL and Cambridge. His PhD was in developmental neurobiology at Cambridge. He is a practising neurologist and scientist working at the forefront of the emerging discipline of Regenerative Neurology, best known for his work in motor neuron disease and multiple sclerosis that combines laboratory and clinical research with a particular focus on human / patient stem cells for his discovery research. Alongside his UK DRI role, Prof Chandran is the MacDonald Chair of Neurology, Director of the Euan MacDonald Centre for Motor Neuron Disease Research and the Anne Rowling Regenerative Neurology Clinic at the University of Edinburgh. He is also a Fellow of the Royal Society of Edinburgh and the Academy of Medical Sciences.

Fiona Ducotterd is Chief Scientific Officer at the Alzheimer's Research UK UCL Drug Discovery Institute (UDDI) and a drug discovery executive with >20 years of global (incl. UK, USA, Japan, China) experience spanning therapeutics research and development, business development and strategic alliances in industry (e.g. MSD, GSK, Eisai, Vertex, Mindset, Shackelford) and academia (UCL). The UDDI team of multidisciplinary scientists is discovering new medicines for neurodegenerative diseases in a biotech-like setting in partnership with leading academic innovators, industry alliances and spin out companies.

Hilary Evans is Chief Executive of Alzheimer's Research UK, the UK's leading dementia research charity and Co-Chair of the Dame Barbara Windsor Dementia Mission. As Chief Executive of ARUK since 2015, Hilary has led the transformation of the charity to one of the leading medical research charities in the UK. She has overseen a significant growth in income, enhancing Alzheimer's Research UK's ability to fund innovative projects. Under her leadership Alzheimer's Research UK has focused on groundbreaking projects that unite charity, academic and private sectors. This has included setting up the pioneering Drug Discovery Alliance of leading academic institutions across the UK; working with venture capital to develop and launch the Dementia Drug Discovery Fund, and working with government and other charities to create the UK Dementia Research Institute. Before joining Alzheimer's Research UK Hilary worked at Age UK, improving the lives of people in later life both in the UK and internationally. Hilary is a Trustee of the Association of Medical Research Charities, a member of the World Dementia Council and holds an honorary doctorate in medicine from The University of Exeter.

Howard Fillit, MD is a geriatrician and neuroscientist, and cofounder and chief science officer for the Alzheimer's Drug Discovery Foundation. He is also a clinical professor of geriatric medicine and palliative care, medicine and neuroscience at the Icahn School of Medicine at Mount Sinai, New York NY.

Chris Fox is an expert in mental health and dementia research. He spent 6 years training in psychiatry and researching trauma/personality assessments and treatment and psychometric assessment development with the Ministry of Defence. Then he went into the NHS and trained in Oxford undertaking an MD on anger characterisation in elderly mentally ill patients at UCL. He then worked in Kent running a memory service, holding a position at KIMHS University of Kent and was the first clinical director at Kent and Medway NIHR Comprehensive Research Network. In 2010 he was appointed as the first Clinical Academic Psychiatrist at Norwich Medical School and Eastern region dementia DeNDRoN lead and he ended up head of department of clinical academic medicine until 2021. His key research themes are: Data and multi-morbidity including applied artificial intelligence; Technology and healthcare; Novel medication CTIMPS relevant to dementia; Brain health – multi-morbidity. Chris is currently leading with 4 health care technology companies on multi-million pound research programmes in software/AI/ technical devices to improve delivery and assessment of health care. Chris is co-medical director of NIHR Health Technology research centre south west.

Franca Gatto is the Director of the Aging, Seniors and Dementia at the Public Health Agency of Canada. Franca works with stakeholder organizations and provincial and territorial governments across Canada, and is the federal government focal point for health issues affecting Canada's older adult population. Through federal investments, partnerships and policy leadership, the Division of Aging, Seniors and Dementia seeks to promote healthy aging in the areas of dementia, injury prevention, and mental health. Fand her team is responsible for the development of Canada's first national dementia strategy, A Dementia Strategy for Canada: Together We Aspire, launched in 2019. Along with her team she is spearheading the implementation of the national dementia strategy and is administering federal investments of over \$100M which support key components of the strategy. Prior to joining the Public Health Agency, Franca gained over 25 years of experience in providing strategic policy and communications advice to decision-makers in the federal Health Portfolio, primarily at Health Canada. Franca holds a Master of Business Administration from the University of Ottawa and a Bachelor of Public Relations from Mount Saint Vincent University in Halifax, Nova Scotia. Franca also completed a Masters Certificate in Public Sector Leadership from Carleton University/Sprott School of Business.

Laurence Geller, CBE, is a businessman, philanthropist and government advisor. As Founder and Chairman of Loveday & Co, Geller has coordinated private, public, academic, and philanthropic partners to create a world-leading provider of specialist dementia care. Geller acts as an expert adviser in both the Department for Health and Social care and the Department for Culture, Media & Sport. In 2023, Geller established the Geller Commission, a review body established to provide recommendations to improve dementia related hospital occupancy.

Jean Georges is the Executive Director of Alzheimer Europe, a position he has held since November 1996. Mr Georges has co-authored and contributed to several academic papers within the field of dementia and Alzheimer's. He has been an invited speaker on dementia policy and research at International, European and national conferences. He has served as the Principal Investigator for Alzheimer Europe in projects supported by IMI and IHI (Innovative Medicines/Health Initiative) and the European Union's Research and Innovation Funding Programmes: FP7, Horizon2020 and Horizon Europe. Prior to joining Alzheimer Europe, he served as a Parliamentary Assistant for members of the Luxembourg and European Parliaments and worked as a journalist in the European and International department of the Luxembourg newspaper "Tageblatt". Mr Georges earned his Bachelor's degree in English and European literature in 1986 from the University of Essex in the United Kingdom.

Ms. Helder has been Minister of Health, Welfare and Sport since January 10, 2024. She previously served as Minister for Long-term Care and Sport from January 10, 2022 to February 2, 2024. She also has these tasks as Minister of Health, Welfare and Sport. She is a member of the VVD. Since 2017, Ms. Helder has been chairman of the board of directors of the Aunt Louise Foundation, which supports organizations and institutions in healthcare. Previously she was director of the University Medical Center Utrecht.

Brian Lawlor is a professor of old age psychiatry at Trinity College Dublin, and deputy executive director of the Global Brain Health Institute. He is a geriatric psychiatrist with an interest in dementia, late-life depression, loneliness and brain health. Brian has worked for over 30 years on developing services and delivering care to people with dementia. His research interests range from early detection and prevention to evaluating new treatments for dementia. Brian also works with different stakeholders, agencies and research groups to understand the determinants of caregiver burden, particularly the impact of loneliness and behavioural and psychological symptoms, with the aim of developing strategies and policies to improve the wellbeing and quality of life of informal caregivers of people with dementia.

Kate Lee, OBE, has been at the forefront of charitable leadership, making a significant impact on the lives of vulnerable individuals and their families for over 30 years. Appointed as Chief Executive of Alzheimer's Society in March 2020, Kate has brought her wealth of experience and passion for social causes to drive positive change in the field of dementia care. Before taking the helm at Alzheimer's Society, Kate served as the Chief Executive of Young Lives vs Cancer. During her four-year tenure, she undertook a transformative journey, rebranding the organisation and instilling new values. Additionally, she founded the Children and Young People's Cancer Coalition, further amplifying her impact in the sector. Prior to her role at Young Lives vs Cancer, Kate served as the CEO of Myton Hospice, a prominent Adult Palliative Care Charity in Coventry and Warwickshire. Here, she worked closely with individuals affected by dementia and their families, gaining valuable insights into the challenges faced by this demographic. In recognition of her outstanding contributions to the charitable sector, Kate Lee was honored with an OBE in the 2023 New Years Honours, a testament to her commitment to creating a better world for those in need.

David Llewellyn is a Professor of Clinical Epidemiology and Digital Health at the University of Exeter Medical School, where he also serves as the Director of Research and Impact at the Departments of Health and Community Sciences and Health and Care Professions. He is a Fellow at the Alan Turing Institute, the UK's national institute for data science and AI, and has an honorary contract with Devon Partnership NHS Trust. After receiving advanced training in epidemiology and data science at the University of Cambridge, he joined Exeter in 2009. David is the Director of the Deep Dementia Phenotyping (DEMON) Network, a global network dedicated to combating dementia and promoting brain health using data science and AI, with over 1,600 members. He co-founded the Alan Turing Institute Interest Group in Precision Dementia Medicine and the ISTAART Professional Interest Area in AI for Precision Dementia Medicine. David also contributes to Alzheimer's Society's Grant Review Board and Alzheimer's Research UK's Clinical Policy Advisory Panel. At the Exeter Institute for Data Science and Artificial Intelligence, he leads the Clinical Theme and serves as the Turing Exeter University Clinical Lead. David is a member of the ISTAART Advisory Council, and has published over 120 articles in leading journals, including JAMA, Lancet Healthy Longevity, JAMA Internal Medicine, JAMA Neurology, and the BMJ.

Sarah Lenz Lock is Senior Vice President for Policy and Brain Health in AARP's Policy, Research and International Affairs (PRI) Department. Ms. Lock leads AARP's policy initiatives on brain health and care for people living with dementia, including serving as the Executive Director of the Global Council on Brain Health, an independent collaborative of scientists, doctors, and policy experts. Ms. Lock also coordinates AARP's role in the Leadership Council of Aging Organizations. Ms. Lock is a frequent writer and public speaker on issues related to healthy aging. Sarah serves on numerous boards and is a member of the American Society on Aging, the Gerontological Society of America, the Dementia Friendly America National Council, the Stakeholder Advisory Committee for the National Institute on Aging's IMPACT Collaboratory, the Dean's Council at the University of Maryland School of Public Health. Sarah represents AARP on the Milken Alliance to Improve Dementia Care and serves as a Health and Aging Policy Fellow Program National Advisory Board Member. She is now leading the Brain Health Action Collaborative, a multi-sector initiative designed to foster a movement towards better brainhealth for all.

Ryoji Noritake is the CEO, and Board Member of Health and Global Policy Institute (HGPI), a Tokyo-based independent and non-profit health policy think tank established in 2004. He also served as Asia-Pacific Lead for Project HOPE, a US-based medical humanitarian aid organization. Through HOPE and HGPI, he has led health system strengthening projects in the Asia-Pacific region and engaged in the US Navy's medical humanitarian projects. His focus is a multi-sectoral approach to health issues such as public-private partnerships and civil-military coordination. He was a member of the Tokyo Metropolitan Government's Policy Discussion Roundtable for Super Ageing Society (2018) and served as a Visiting Scholar at the National Graduate Institute for Policy Studies (2016-2020). He is currently serving as a member of World Dementia Council (WDC), the Salzburg Global Seminar's Advisory Council, Advisory Board Member of Elsevier Atlas, and the Dementia Innovation Alliance hosted by the Ministry of Economy, Trade and Industry (METI), Japan. He was awarded the 32th Takemi Incentive Award in 2022. He is a graduate of Keio University's Faculty of Policy Management and holds a MSc in Medical Anthropology from the University of Amsterdam, the Netherlands.

John O'Brien is Professor of Old Age Psychiatry in the Department of Psychiatry at the University of Cambridge. He is a National Institute for Health Research (NIHR) Emeritus Senior Investigator and a Fellow of the UK Academy of Medical Sciences. He is the NIHR Clinical Research Network National Specialty Lead for Dementia. His main research interests are in the clinical and research application of imaging biomarkers in dementia, dementia with Lewy bodies and clinical trials. He has been a member of the National Institute for Health and Social Care Excellence (NICE), British Association of Psychopharmacology, European Federation of Neurological Sciences and European Stroke Association Dementia Guideline groups.

Joanne Pike, DrPH, is president and CEO of the Alzheimer's Association®, the global leader in Alzheimer's and dementia care, support and research. With her progressive experience in social support and public health, she is leading the organization during a transformational period as novel treatments are emerging. Since joining the Alzheimer's Association in 2016, Dr. Pike has held several roles, highlighting her increasing leadership within the organization and the cause. During her 25 years in public health, she successfully leveraged public and system policy to advance public health outcomes with a particular emphasis on outreach to underrepresented and underserved communities. Dr. Pike is also president and CEO of the Alzheimer's Impact Movement (AIM), a separately incorporated advocacy affiliate working to advance and develop policies to overcome the disease.

June Raine, DBE, is CEO of the Medicines and Healthcare products Regulatory Agency. She trained in medicine in Oxford after completing a master's degree by research in Pharmacology. Her interest in drug safety led to a career in medicines regulation which has spanned a number of roles in assessment, management and strategic development within the UK national authority. She was elected in 2012 as the first chair of the European Pharmacovigilance Risk Assessment Committee and is also co-Chair of the WHO Advisory Committee on Safety of Medicinal Products. Her special interests are in monitoring the outcomes of regulatory action, risk communication and patient involvement in the regulatory process.

Dame Louise Robinson, is an academic GP and Professor of Primary Care and Ageing at Newcastle University. She was the first GP to be awarded a prestigious NIHR Professorship, followed by a NIHR Senior Investigator award. Professor Robinson also holds a UK Regius Professorship in Ageing and was awarded a Dame hood in 2018 for services to the care and research of older people. Louise's personal research programme is focused on improving quality of life and quality of care for older people, especially those living with dementia. She leads 1 of 3 Alzheimer Society national Centres of Excellence on Dementia Care and a NIHR Global Health group on Dementia Prevention and Care. Louise was primary care lead for the Prime Minister's Dementia Challenge and was a member of the NICE Dementia Care Guidelines development group.

Philip Scheltens studied at the VU University Amsterdam, Netherlands, gaining his MD in 1984, and PhD in 1993. He was appointed as Professor of Cognitive Neurology in 2002 and founded the Alzheimer Center at Amsterdam University Medical Centers in that same year, which he directed until 2022. Currently he is partner at EQT group and heads the Dementia Fund at EQT Life Sciences, that he started in 2020. He has been the (inter)national PI for over 35 studies, including phase 1-3 multicenter clinical trials. He supervised >100 PhD theses since 2000. He founded and led the Dutch National Plan against dementia and served as chair of the board until 2021. He currently sits on the advisory panel of the Dutch National Strategy for Dementia 2022-2030. Philip served as co-editor-in-chief of Alzheimer's Research & Therapy from 2013-2022 and co-led various EU projects. He authored over 1100 peer reviewed papers and > 75 book chapters and co-edited several major text books. He is member of the Royal Dutch Academy of Arts and Sciences (KNAW) since 2011 and member of the board from 2015-2020. In 2016 he was awarded the European Grand Prix for Alzheimer's Research. In 2020 he was Knighted in the Order of the Netherlands Lion by the King of the Netherlands. In 2021 he was elected honorary member of the European Academy of Neurology. He acts as chair of the World Dementia council since 2021. In 2023 he received the Bengt Winblad Life Time Achievement Award.

Katrin Seeher is a Mental Health Specialist working in WHO's Brain Health Unit. She is responsible for the implementation of the global action plan on the public health response to dementia 2017-2025 and its monitoring framework, the Global Dementia Observatory (GDO). She led the development of WHO's "Global status report on the public health response to dementia" and is assisting Member States in developing their national dementia plans and formulating country-level responses to dementia.

Lenny Shallcross is Executive Director of the World Dementia Council. Prior to leading the World Dementia Council Lenny held senior policy and advocacy roles at the Alzheimer's Society in the UK. He worked in the UK government as a special adviser in several government ministries as well as working in Parliament and for the Labour Party.

Johannes Streffer (MD) is Senior Vice President and Head of Global Clinical Development of Lundbeck and visiting professor in the Department of Biomedical Sciences, University of Antwerp. Johannes is neurologist and psychiatrist; he received his training from the University of Tübingen/ Germany, including his residency in Neurology, before he joined the department of Psychiatry Research at University of Zurich. Before joining Lundbeck in October 2023, he held positions as CMO of AC Immune SA (Lausanne/ Switzerland) and VP, Head of Translational Medicine Neuroscience at UCB Biopharma SPRL. He started his industry career at Janssen, Pharmaceutical companies of J&J. Johannes has more than 30 years of clinical research experience in neuropsychiatry, both as an investigator and as a researcher in the pharmaceutical industry, spanning all phases of clinical development, with a focus on early experimental trials in neurodegeneration and harnessing biomarkers for patient identification, early translation as well as accelerated approval. Johannes has been EFPIA lead for EMIF-AD, part of the IMI-EMIF (56 partners; 14 European countries represented; 56MM € worth of resources; “3 projects in one”), that integrated a wide variety of AD data cohorts, biomarker rich single center cohorts to EHRs, to foster the understanding of early markers and change in the prodementia AD spectrum.

Arthur W. Toga, Ph.D., is Provost Professor of Ophthalmology, Neurology, Psychiatry and the Behavioral Sciences, Radiology and Biomedical Engineering, and Director of the USC Mark and Mary Stevens Institute of Neuroimaging and Informatics. Dr. Toga’s research focus is on neurodegenerative disease and specifically works on Alzheimer’s disease. He has pioneered some of the most widely used informatics systems in the world (e.g., IDA and GAAIN), supporting more than 170 multisite trials in AD and other neurological diseases and psychiatric disorders. He is an author or co-author of more than 950 peer-reviewed papers, 1100 abstracts and 80 book chapters or books, among them Brain Mapping: The Methods. He is the founding editor of the journal NeuroImage. Dr. Toga has received numerous awards for his research and teaching, including the Pioneer in Medicine Award, Smithsonian Award for Scientific Innovation and Giovanni DiChiro Award for Outstanding Scientific Research. He holds the Ghada Irani chair in Neuroscience and has been one of the world’s top researchers on the AD Scientific Index, Top 200 Best Scientists in Neuroscience on Research.com, and listed as one of Thomson Reuters’ and Clarivate Highly Cited Researchers for many years.

Argonde van Harten, MD PhD, is a neurologist and senior researcher at the Amsterdam UMC, location VUmc. Her research focusses on an accurate early diagnosis of Alzheimer’s disease, for example by using plasma biomarkers.

George Vradenburg is the Chairman of the Davos Alzheimer’s Collaborative, a global platform to link and scale basic and clinical interventions to prevent Alzheimer’s and Related Dementias across low, middle and high income resource settings. DAC works with families living with the disease, Biopharmaceutical companies, governments, health systems and scientists around the world to assure that Alzheimer’s interventions are accessible to all populations not just those of Western European lineage, who are living in cities and who have significant resources.

Event sponsors



AARP

AARP is the largest nonprofit, nonpartisan organization in the United States dedicated to empowering Americans 50 and older to choose how they live as they age. With a nationwide presence, AARP strengthens communities and advocates for what matters most to the more than 100 million Americans 50-plus and their families: health security, financial stability and personal fulfillment. AARP also works for individuals in the marketplace by sparking new solutions and allowing carefully chosen, high-quality products and services to carry the AARP name. As a trusted source for news and information, AARP produces the nation's largest circulation publications, AARP The Magazine and AARP Bulletin. To learn more, visit www.aarp.org/about-aarp/, www.aarp.org/español follow @AARP, @AARPenEspañol and @AARPadvocates on social media. AARP also convenes the Global Council on Brain Health, an independent collaborative created to provide trusted information on how people can maintain and improve their brain health as they age.

aarp.org/brainhealth



Alzheimer's Society

Alzheimer's Society is the UK's leading dementia charity and the only one to tackle all aspects of dementia by giving help and hope to people living with dementia today and in the future. We give vital support to people facing the most frightening times of their lives, while also funding groundbreaking research and campaigning to make dementia the priority it should be. As a Society, we are made up of people with dementia, carers, trusted experts, campaigners, researchers and clinicians. We are the UK's largest collective force of people with unparalleled knowledge and over 40 years of experience addressing the biggest challenges facing people living with dementia.

alzheimers.org.uk



Alzheimer's Drug Discovery Foundation (ADDF)

Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than \$290 million to fund over 750 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 20 countries.

www.alzdiscovery.org

LOVE DAY

Loveday & Co

Loveday & Co is a healthcare and hospitality company providing Care Beyond Compare in some of the most exclusive neighbourhoods in London. Loveday operates beautiful properties offering care to those living with dementia and age-related conditions, and we believe nothing should stop Members from enjoying life as they always have. Our mission is to help raise the standards of dementia care throughout the sector.

Partnership organisations



Alzheimer's Association

The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research. The Association works to provide care and support for all those affected by Alzheimer's and all other dementia. As the largest nonprofit funder of Alzheimer's research, the Association is committed to accelerating the global progress toward methods of treatments, preventions and ultimately, a cure. The Association currently has more than \$405 million invested in over 1,100 active projects in 56 countries spanning six continents. The Association is the leading voice for Alzheimer's disease advocacy, ensuring that the need for Alzheimer's care, education and research is heard at every level of government.

Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®.



Davos Alzheimer's Collaborative

The Davos Alzheimer's Collaborative is a groundbreaking global initiative that unites experts from public and private sectors to combat the escalating crisis of Alzheimer's disease. Spearheaded by the World Economic Forum and The Global CEO Initiative on Alzheimer's Disease, this collaborative effort mirrors successful models like GAVI and CEPI, emphasizing the need for a coordinated global response to address Alzheimer's as a silent pandemic. With a mission to accelerate innovation in drug development, healthcare practices, and awareness, the collaborative is investing over \$700 million over six years to drive progress in combating Alzheimer's. By building a global clinical trial network, advancing healthcare system preparedness, and focusing on early detection and risk reduction efforts, the Davos Alzheimer's Collaborative is at the forefront of pioneering solutions to tackle this pressing public health challenge.



Home Instead

About Home Instead, an Honor company

Home Instead, Inc. and its parent company, Honor, are expanding the world's capacity to care. With the world's largest home care network and the most advanced care platform, Honor and Home Instead are revolutionizing care for older adults, their families, and Care Professionals. Home Instead, Inc. is the premier home care franchisor through its network of independently owned and operated Home Instead franchise businesses. These enable older adults to live safely and comfortably in their own homes for as long as possible. Its unique service is tailored to the needs of individual clients and the amount of care they require to be able to continue to live in the comfort and familiarity of their own home as long as possible. Services span the care continuum – from providing personal care to specialized Alzheimer's care and hospice support. Combined, the network has more than 100,000 Care Professionals across 13 countries, meeting the growing needs of millions of older adults and their families worldwide. For more information, visit joinhonor.com and homeinstead.com.